Growth in Prevalence of Autoimmune Diseases Estimated to Drive Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market: Ken Research REQUEST FOR SAMPLE REPORT Buy Now Request For sample Report × Report Title Name Email Designation Phone No Comapny Name Comapny URL Country -- Please Select Your Country -- Afganistan Africa Albania Algeria Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Aruba Asia Australasia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire Bosnia Herzegovina Botswana Brazil BRICS British Virgin Islands Brunei Darussalam Bulgaria Burkina Faso Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Central and South America Chad Chile China Colombia Comoros Congo Costa Rica Cote d'Ivoire Croatia Cuba Curacao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Europe European Union Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Global Great Britain Greece Greenland Grenada Guadeloupe Guam Guatemala Guerney & Alderney Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Ivory Coast Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Man (Island of) Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Middle East Minnesota Moldova Monaco Mongolia Monserrat Montenegro Morocco Morroco Mozambique Myanmar Namibia Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue North America North Korea Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Helena Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa Samoa (American) San Marino Sao Tome and Principe Saudi Arabia Scandinavia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon (Islands) Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands Western Sahara Yemen Zambia Zimbabwe Requirement Submit Chronic inflammatory demyelinating polyneuropathy or CIDP is a neurological disorder in which the body immune system attacks myelin which is a vital part of the nervous system. It occurs when the body immune system cannot distinguish between the body’s own cell and foreign cell and instead start destroying the healthy cells of the body. It is also known as chronic relapsing polyneuropathy. This can cause impaired ability, pain, loss of sensation, chronic fatigue and other problems, Different treatments can be used to treat the disease for instance intravenous immunoglobulin, physiotherapy, plasmapheresis, and others. Some of the symptoms are both proximal and distal, orthostatic dizziness, initial limb weakness, tingling and numbness of hands & feet. According to study, “Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Information By Treatment (Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis (Plasma Exchange), Physiotherapy, Others), Diagnosis (Electrodiagnostic Testing, Nerve Conduction, EMG, Spinal Fluid Analysis, Others), By Route of Administration (Intravenous, Oral, Others), By End User (Hospitals, Specialty Neurological Clinics, Research & Academic Laboratories, Others) and Top Regions Forecast till 2023” the key companies operating in the global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market are Octapharma AG, Shire, Kedrion S.p.A, Mitsubishi Tanabe Pharma Corporation, Grifols, Baxter, Momenta Pharmaceuticals Inc., Argenx SE, Immupharma Plc., Pfizer Inc., GeNeuro SA, Teijin Pharma Ltd, Takeda Pharmaceutical Co Ltd., UCB SA. Based on treatment, Chronic Inflammatory Demyelinating Polyneuropathy market is segmented into intravenous immunoglobulin (IVIG), plasmapheresis (plasma exchange), corticosteroids, physiotherapy and others. IVIG segment dominates the market owing to its preference as the first line of treatment against CIDP. Based on diagnosis, market is segmented into electro-diagnostic testing, EMG, nerve conduction, spinal fluid analysis and others. Based on route of administration, market is segmented into oral, intravenous and others. Based on distribution channel, market is segmented into retail pharmacy, hospital pharmacy and online pharmacy. In addition, based on end-user, market is segmented into hospitals, research & academic laboratories, specialty neurological clinics and others. The Chronic Inflammatory Demyelinating Polyneuropathy market is driven by rise in research & development (R&D) related to plasma-derived medicines, followed by growth in prevalence of autoimmune diseases, rise in government support via awareness programs & drug approvals and increase in awareness about Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). However, high cost of the IVIG treatment and side-effects associated with the IVIG treatment such as hypotension, lower back pain, flushing, nausea, chills, wheezing, etc. may impact the market. Moreover, growth in advancements in the treatment is a key opportunity for market. Based on geography, the North-American region holds major share, followed by European region in Chronic Inflammatory Demyelinating Polyneuropathy market owing to growth in healthcare infrastructure and active government support in the region. The Asian-Pacific region is anticipated to witness lucrative growth rate due to rise in emphasis by healthcare organizations & government over the forecast period. It is projected that the market will be reached at rapid pace on account of high population & growth in per capita healthcare spending and increase the prevalence rate of CIDP during the forecast period. The market is developing at a CAGR of 6.2% and is estimated to reach US $3907.17 million by the end of the forecast period 2018-2023. To know more, click on the link below:- Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Related Reports:- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2019 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)-Pipeline Review, H2 2017 Contact Us:– Ken Research Ankur Gupta, Head Marketing & Communications ankur@kenresearch.com +91-9015378249 Post Views: 18 Tags: Africa Chronic Inflammatory Demyelinating Polyneuropathy Market, Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy Market, Baxter Chronic Inflammatory Demyelinating Polyneuropathy Market, Canada Chronic Inflammatory Demyelinating Polyneuropathy Market, Europe Chronic Inflammatory Demyelinating Polyneuropathy Market, France Chronic Inflammatory Demyelinating Polyneuropathy Market, Germany Chronic Inflammatory Demyelinating Polyneuropathy Market, Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, Global Chronic Inflammatory Demyelinating Polyneuropathy Industry, Global Chronic Inflammatory Demyelinating Polyneuropathy Industry Research, Global Chronic Inflammatory Demyelinating Polyneuropathy Industry Research Report, Global Chronic Inflammatory Demyelinating Polyneuropathy Market, Global Chronic Inflammatory Demyelinating Polyneuropathy Market Analysis, Global Chronic Inflammatory Demyelinating Polyneuropathy Market Application, Global Chronic Inflammatory Demyelinating Polyneuropathy Market Forecast, Global Chronic Inflammatory Demyelinating Polyneuropathy Market Future Outlook, Global Chronic Inflammatory Demyelinating Polyneuropathy Market Growth, Global Chronic Inflammatory Demyelinating Polyneuropathy Market Key Players, Global Chronic Inflammatory Demyelinating Polyneuropathy Market Research, Global Chronic Inflammatory Demyelinating Polyneuropathy Market Research Report, Global Chronic Inflammatory Demyelinating Polyneuropathy Market Revenue, Global Chronic Inflammatory Demyelinating Polyneuropathy Market Scope, Global Chronic Inflammatory Demyelinating Polyneuropathy Market Share, Global Chronic Inflammatory Demyelinating Polyneuropathy Market Size, Global Chronic Inflammatory Demyelinating Polyneuropathy Market Trends, Global CIDP Industry, Global CIDP Market, Global CIDP Market Analysis, Global CIDP Market Forecast, Global CIDP Market Future Outlook, Global CIDP Market Growth, Global CIDP Market Key Players, Global CIDP Market Revenue, Global CIDP Market Trends, Globaler Markt für chronisch entzündliche demyelinisierende Polyneuropathie (CIDP), Grifols Chronic Inflammatory Demyelinating Polyneuropathy Market, India Chronic Inflammatory Demyelinating Polyneuropathy Market, Kedrion S.p.A Chronic Inflammatory Demyelinating Polyneuropathy Market, Marché mondial de la polyneuropathie inflammatoire démyélinisante chronique (CIDP), Mercato globale della polineuropatia demielinizzante infiammatoria cronica (CIDP), Middle East Chronic Inflammatory Demyelinating Polyneuropathy Market, Mitsubishi Tanabe Pharma CIDP Market, Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy Market, Octapharma Chronic Inflammatory Demyelinating Polyneuropathy Market, Piața globală de polineuropatie demielinizantă inflamatorie cronică (CIDP), Shire Chronic Inflammatory Demyelinating Polyneuropathy Market, South America Chronic Inflammatory Demyelinating Polyneuropathy Market, Thị trường bệnh viêm đa dây thần kinh mãn tính toàn cầu (CIDP), U.K Chronic Inflammatory Demyelinating Polyneuropathy Market, U.S. Chronic Inflammatory Demyelinating Polyneuropathy Market, Παγκόσμια αγορά χρόνιας φλεγμονώδους απομυελινωτικής πολυνευροπάθειας (CIDP), Глобальный рынок хронической воспалительной демиелинизирующей полиневропатии (CIDP), السوق العالمي للالتهابات المزمنة لإزالة الالتهابات (CIDP), 世界の慢性炎症性脱髄性多発神経障害(CIDP)市場, 全球慢性炎性脱髓鞘性多发性神经病(CIDP)市场